ARTICLE | Clinical News
Ribozyme begins Phase II with Angiozyme
February 8, 2001 8:00 AM UTC
RZYM and partner Chiron (CHIR) began an open-label U.S. Phase II study of the Angiozyme anti-angiogenic ribozyme in breast cancer patients. Angiozyme targets the VEGF receptor. ...